Sanofi Aventis then agreed to come up with a list of different names...

Up until very recently nobody knew why the weight loss drug Acomplia made by the pharmaceutical giant Sanofi Aventis was going to be named Zimulti in the United States of America. The name Acomplia was widely accepted in Europe and was fast gaining brand recognition as a weight loss drug and the word Acomplia had the advantage of sounding like ‘accomplishment’ which is encouraging for people losing weight.

However the Food and Drug Administration in America have a rule which is that drug names must not sound or give the idea that they can do something for you and therefore because Acomplia sounds like ‘accomplishment’ the FDA asked the FDA to come up with a different name for it. Sanofi Aventis then agreed to come up with a list of different names and asked the FDA to choose one which they felt was appropriate.

In the same way the weight loss drug Reductil which is similar to the word ‘reduction’ was not given the green light in America and as a result in the United States it is known as Meridia. The idea is that patients will not know from the name of the drug what it can do for you and so they will be less likely to try and prescribe themselves medicine.

The Food and Drug Administration is known to be extremely exacting and thorough when it comes to the okaying of medicines in America and at Ukmedix news we think that this is a very prudent thing to do. America also has the most litigation in the world and therefore any drug that causes harmful side effects that were unnoticed during clinical testing will end up being hauled through the courts and huge financial damages enacted on the company that makes the drug.

Acomplia has been extensively tested not only in America but even in Europe and works as an appetite suppressant as well as a drug that can help diabetics with metabolic problems.